Luckwel Pharmaceuticals Inc. Stock price

LWEL

US54959L1017

Investment Holding Companies

Delayed OTC Markets Other stock markets 10:13:51 2021-10-13 am EDT			5-day change	1st Jan Change
3.5 ^USD	+75.00%		-.--%	-.--%

2021	Luckwel Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended June 30, 2020	CI
2021	Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended March 31, 2020	CI

Chart Luckwel Pharmaceuticals Inc.

Duration

Period

Style

Dynamic Chart

Latest news about Luckwel Pharmaceuticals Inc.

Luckwel Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended June 30, 2020	2021	CI
Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended March 31, 2020	2021	CI
Luckwel Pharmaceuticals Inc. announced that it expects to receive $0.075 million in funding from Bounty Company Limited	2021	CI
Luckwel Pharmaceuticals Inc. announced that it expects to receive $0.12 million in funding	2021	CI
Luckwel Pharmaceuticals Inc. Announces Address Changes	2021	CI
Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2019	2020	CI
Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter Ended September 30, 2019	2019	CI
Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended March 31, 2019	2019	CI
Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2018	2019	CI
Luckycom Pharmaceuticals Inc. has Changed its Name to Luckwel Pharmaceuticals Inc	2018	CI
Luckwel Pharmaceuticals Inc. has Changed its Ticker to LWEL from LCOM	2018	CI
Luckycom, Inc. will Change its Name to Luckycom Pharmaceuticals Inc	2017	CI
Luckycom Pharmaceuticals Inc. will Change its Ticker to LCOM from LKYM	2017	CI
Luckycom Inc Auditor Raises 'Going Concern' Doubt	2016	CI
Luckycom Inc Announces Fiscal Year Change from February 28 or 29 to March 31	2016	CI

More news

Press releases Luckwel Pharmaceuticals Inc.

LUCKWEL PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	2021	AQ
LUCKWEL PHARMACEUTICALS : Changes in Registrant's Certifying Accountant, Non-Reliance on Previous Financials, Audits or Interim Review, Financial Statements and Exhibits (form 8-K/A)	2021	AQ
LUCKWEL PHARMACEUTICALS INC. : Changes in Registrant's Certifying Accountant, Non-Reliance on Previous Financials, Audits or Interim Review (form 8-K)	2021	AQ
LUCKWEL PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	2021	AQ
LUCKWEL PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	2021	AQ

More press releases

Managers and Directors - Luckwel Pharmaceuticals Inc.

Managers	Title	Age	Since
Kingrich Lee CEO	Chief Executive Officer	48	2013

Members of the board	Title	Age	Since
Kingrich Lee CEO	Chief Executive Officer	48	2013

More insiders

Luckwel Pharmaceuticals Inc. creates medicine to cure diseases. The Company is focused on autoimmune disease, human immunodeficiency virus (HIV) / acquired immune deficiency syndrome (AIDS) and infectious diseases. The Companyâs pipelines include LWEL-2120 for the treatment of rheumatoid arthritis (RA), LWEL-2119 for the treatment of HIV and LWEL-2103 for the treatment of COVID-19.

Sector

Investment Holding Companies

More about the company

Sector Shell Companies

	1st Jan change	Capi.
LUCKWEL PHARMACEUTICALS INC.	-.--%	515 M $
BRILLIANT N.E.V. CORP.	-2.60%	1 722 M $
NINE ALLIANCE SCIENCE & TECHNOLOGY GROUP	-.--%	1 125 M $
SCREAMING EAGLE ACQUISITION CORP.	+6.34%	991 M $
CHURCHILL CAPITAL CORP VII	+5.32%	971 M $
YUBICO AB	+17.00%	914 M $
GORES HOLDINGS IX, INC.	+6.48%	690 M $
ARES ACQUISITION CORPORATION II	0.00%	650 M $
DIGITAL WORLD ACQUISITION CORP.	+14.47%	638 M $
PREVENTION INSURANCE.COM	+34.07%	614 M $